What Distalmotion does

Distalmotion SA is a Swiss medical device company founded in 2012 as a spin-off from the EPFL Robotics Lab in Lausanne, headquartered in Epalinges, Switzerland with approximately 150 employees representing over 25 nationalities. The company develops and commercializes the DEXTER Robotic Surgery System, a compact, mobile soft-tissue surgical robot purpose-built for the ambulatory surgery center (ASC) and outpatient hospital market where conventional robotic platforms face adoption barriers around footprint, cost, and workflow. The system consists of a sterile surgeon console (DEXTER L6), mobile patient carts, an open-architecture endoscope arm compatible with all 5–10mm endoscopes (including 4K fluorescence), and a suite of single-use fully wristed instruments; key technical differentiators include a ~4-minute setup time, a 125 sq ft footprint, sterile console that keeps the surgeon within the sterile field, and a hybrid modality allowing seamless switching between robotic and laparoscopic approaches without redocking.

The company's revenue model centers on capital equipment sales of the DEXTER system to hospitals and ASCs, complemented by recurring service and support (including per-procedure clinical specialist coverage) and training services delivered through Dexter Academy. Pricing is quote-based with multi-year contracts and tailored financing solutions; specific ASP is not publicly disclosed but typical surgical robot ASPs run $1M+. Distribution is direct via enterprise field sales, targeting US ASC networks and multi-site hospital systems. Commercial momentum is building through high-profile accounts including AdventHealth (first multi-system US deployment across its 50-hospital network), HonorHealth-affiliated ASCs, SCA, Surgery Partners, and Cypress Surgery Center, with over 3,000 patients treated across 30+ procedure types by 100+ surgeons in Europe and the US.

The company has cumulatively raised over $390 million across multiple late-stage venture rounds (Series E $90M in January 2022, Series F $150M first close in April 2023, Series G $150M in November 2025) led by Revival Healthcare Capital, with a strategic investment from Johnson & Johnson Innovation (JJDC) in January 2026. Distalmotion holds CE mark since 2020 across urology, gynecology, and general surgery, and four FDA 510(k) clearances including a June 2026 clearance for sacrocolpopexy, sacrocervicopexy, sacrohysteropexy, and endometriosis resection procedures, with authorization to begin a US myomectomy clinical trial.

Name

Distalmotion

Legal name

Distalmotion SA

Website

https://distalmotion.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

101–250 employees

Short description

Distalmotion SA is a Swiss medical device company developing the DEXTER compact soft-tissue surgical robot for ASCs and outpatient hospitals, selling capital equipment, service, and training directly to US hospital networks and ambulatory surgery centers.

Ownership category

akta.pro rank

Product category

Surgical Robotics

NAICS

Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Surgical Robotics & Computer-Assisted Surgery Platforms (HLAHADAF)

akta.pro secondary industries

Healthcare & Assistive Robotics (HDAAAIAC), Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS) (HLAHADAA), Endourology & Minimally Invasive Urologic Surgery (HLAKAOAF)

Keywords

• Surgical robotics
• Robotic surgery systems
• Minimally invasive surgery
• Ambulatory surgical care
• Medical device manufacturing

Headquarters

HQ city

Epalinges

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations

Revenue model

1. DEXTER Surgical Robot System Sales: Sale of the DEXTER robotic surgery system to hospitals and ambulatory surgery centers. The company provides flexible, cost-effective financing options to make the system economically accessible. Revenue from initial capital equipment sale with potential for service and support contracts.
2. Service and Support: Ongoing customer service and support including expert clinical specialists providing case support in every procedure alongside surgical teams as they progress up the learning curve.
3. Training Services (Dexter Academy): State-of-the-art training curriculum for surgeons and surgical teams delivered through Dexter Academy to reach Dexter proficiency, including e-learning, simulator training, and hands-on training sessions.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels9 records

Core offering

Distalmotion develops, manufactures, and sells the DEXTER Robotic Surgery System, a compact and mobile soft tissue surgical robot that integrates into any operating room without structural modifications. The system comprises a sterile surgeon console, mobile patient carts, an open-architecture endoscope arm, and a suite of single-use fully wristed instruments, and is purpose-built for outpatient/ambulatory settings as well as hospital general surgery, gynecology, and urology use.

Product overview

Distalmotion offers the DEXTER® Robotic Surgery System as its primary product—a small, mobile surgical robot designed for soft tissue procedures in general surgery, urology, and gynecology. The system consists of the L6 Surgeon Console, L6 Patient Carts, an open architecture endoscope arm, and a suite of fully wristed single-use instruments. Supporting the core product is Dexter Academy, a comprehensive training program that includes e-learning modules, simulator training, and hands-on training sessions for surgeons and nurses. The company holds multiple trademarks including DEXTER - THE SURGEONS ROBOT™ and DEXTER ON-DEMAND ROBOTICS™. DEXTER is CE marked for Europe and FDA cleared for specific procedures in the US, particularly targeting the Ambulatory Surgery Center market.

Differentiator

Problem solved

Functional benefit

Brands

• DEXTER: DEXTER is a soft tissue surgical robot system designed to simplify robotic surgery operations, enabling more surgeons in more operating rooms to provide robotic surgery benefits to more patients.

Products and services

• DEXTER Robotic Surgery System A small, mobile, soft-tissue surgical robot system designed to integrate into any operating room without infrastructure modifications. Features a sterile surgeon console, open architecture compatible with existing instrumentation, ~4 minute setup time, hybrid robotic/laparoscopic capability, and a suite of single-use fully wristed instruments. Sold to hospitals and ambulatory surgery centers for general surgery, urology, and gynecology procedures.
• Dexter Academy State-of-the-art training curriculum developed with expert teaching centers and clinicians that equips surgeons and surgical teams with the knowledge and skills to reach DEXTER proficiency. Includes e-learning modules, simulator training, and hands-on training sessions. Sold as part of the customer onboarding and adoption program for hospitals, ASCs, and surgical teams.

Quantifiable outcome

• Setup time under 4 minutes vs competitors requiring significantly more time
• +4 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Five partnerships are on record, tiered flagship, core and major.

• AdventHealthflagshipStrategic or Co-development PartnerFirst multi-system sale in US market. AdventHealth, operating 50 hospitals across nine states, purchased DEXTER system for deployment across hospital network. Completed first cases as part of effort to expand robotic surgery in outpatient departments.
• EPFL (Swiss Federal Institute of Technology Lausanne)coreStrategic or Co-development PartnerDistalmotion founded in 2012 as spin-off from EPFL Robotics Lab. Company developed DEXTER in collaboration with expert teaching centers and clinicians. EPFL Innogrant program contributed to company founding.
• HonorHealthmajorStrategic or Co-development PartnerASCs affiliated with HonorHealth adopting DEXTER system as part of commercial expansion in US outpatient surgery market.
• SCA (Surgical Care Affiliates)majorStrategic or Co-development PartnerASC network adopting DEXTER system as part of growing commercial momentum in US outpatient surgery center market.
• Surgery PartnersmajorStrategic or Co-development PartnerASC network adopting DEXTER system for outpatient surgical procedures in US market expansion.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Intuitive Surgical: Dominant incumbent in robotic-assisted surgery with the da Vinci platform, controlling the majority of the global installed base in soft tissue robotics. Directly competes with DEXTER in general surgery, urology, and gynecology, but its systems are larger, more expensive, and hospital-centric.
• Medtronic: Global medtech incumbent that launched the Hugo RAS system, a modular robotic-assisted surgery platform for urology, gynecology, and general surgery. Competes broadly in the same surgical robotics category as DEXTER but as part of a much larger portfolio.
• Johnson & Johnson: Major medtech incumbent developing its own soft tissue surgical robotics platform (Ottava) and the Monarch endoluminal system. Both a strategic investor in Distalmotion (via JJDC) and a competitor with overlapping product roadmaps.
• Stryker: Major medtech incumbent with the Mako robotic platform in orthopedics. While focused on a different surgical specialty (orthopedics), Stryker represents a broader competitive model of incumbent surgical robotics expansion that could eventually encroach on DEXTER's indications.

Direct peers

• CMR Surgical: UK-based developer of the Versius surgical robotic system, a small, modular soft tissue robot positioned similarly to DEXTER for general surgery, gynecology, and urology. Direct competitor targeting cost-constrained settings and ambulatory care, with overlapping FDA/CE regulatory pathway.
• Moon Surgical: French-American surgical robotics company developing a compact, versatile soft tissue robotic platform also aimed at expanding robotic surgery access to outpatient and ambulatory settings. Direct competitor to DEXTER in the small-footprint robotic surgery niche.
• Asensus Surgical: Developer of the Senhance surgical system, a digital laparoscopy platform with robotic-like features targeting general surgery, gynecology, and urology. Direct competitor in the soft tissue minimally invasive surgical robotics space, with a more cost-sensitive positioning similar to DEXTER.

Emerging players

• Vicarious Surgical: Emerging surgical robotics company developing a single-port robotic system for abdominal procedures. Earlier-stage than Distalmotion, with partial overlap in soft tissue robotics and a similar focus on improving access and reducing footprint.
• Activ Surgical: Emerging surgical intelligence and robotics company focused on intraoperative visualization and AI-assisted surgery. Partial overlap with DEXTER's surgical workflow enhancement value proposition, but more focused on software/AI than full robotic platforms.

Others

• Renishaw: UK-based engineering company with surgical robotics and neurosurgical navigation products. Adjacent player in surgical robotics but focused primarily on neurological and stereotactic procedures rather than the soft tissue general surgery market where DEXTER competes.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/distalmotion
• YouTubeyoutube.com/@distalmotion
• LinkedInlinkedin.com/company/distalmotion

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds10 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Distalmotion